MainStreet Investment Advisors Acquires Zimmer Biomet Stake; Insider Sells Stake

Financial Advisors


Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been the subject of major acquisition news recently as MainStreet Investment Advisors LLC acquired a new stake in a medical device provider. MainStreet Investment Advisors LLC has acquired 5,199 shares of Zimmer Biomet stock valued at approximately $663,000, according to a recent 13F filing with the Securities and Exchange Commission (SEC).

The acquisition news follows an insider sale by VP Chad F. Phipps, who sold 23,045 shares of Zimmer Biomet on Friday, March 17. The sale was disclosed in legal documents to the SEC that can be accessed through the SEC’s website. Following the transaction, Phipps now directly owns 43,671 shares of Zimmer’s Biomet shares worth $5,437,039.50. This latest activity means the insider now owns his 0.95% stake in Zimmer Biomet.

Despite news of this insider sale and acquisition making headlines recently, Zimmer Biomet’s stock opened at $138.35 on Friday, unchanged from the previous day’s price. The company has a 50-day moving average of $126.96 and a 200-day moving average of $121.94.

In terms of financial and market performance data, as reported by Yahoo Finance earlier this year on February 1st, Zimmer Biomet Holdings Inc delivered strong results in the fourth quarter of fiscal year 2020. Such as higher than expected earnings per share (2%, about $2) than Reuters estimate ($1.96). In addition, net sales increased approximately 0.5% (over $2 billion) and adjusted operating margin expanded more than three times his, reaching 14% from 48% at Q4 2019 levels. bottom.

Overall, current indicators look very positive for Zimmer Biometric Holdings, Inc., despite some recent changes in leadership and investment relationships within the company.

Shareholders Show Confidence in Zimmer Biomet as Big Investor Increases Stake


Zimmer Biomet, a leading medical device provider, has seen some movement in its shareholder base. Large investors such as Crossmark Global Holdings Inc., HB Wealth Management LLC, Creative Financial Designs Inc. ADV, Farmers & Merchants Investments Inc. and DAVENPORT & Co LLC have all increased their stakes in the company in recent months. increase. Hedge funds and other institutional investors currently own 87.21% of his shares. Zimmer Biomet has recently received various analyst reports, with two analysts providing sell ratings, six analysts providing hold ratings, and seven analysts providing buy ratings. is recommended. However, according to data from Bloomberg.com, the average rating is “pending” and the consensus price target is $134.19.

Vice President Chad F. Phipps recently sold 23,045 shares of Zimmer Biomet at $124.50 per share. The deal was described in his SEC filings corresponding to this time.

Despite this move within Zimmer Biomet’s ownership structure, analysts reported earnings per share (EPS) of $1.88 for the fourth quarter 2016 fiscal quarter, with a final earnings result of It was encouraging for investors. Compared to analyst forecasts set around the historic fourth quarter revenue forecast of US$1.76 billion average last year. ZBH revenues were up 2%, significantly ahead of the prior year period.

In addition to these positives that stand out among peer comparison figures, the quarterly update of peers shows that ZBH recently announced a quarterly dividend to be paid to shareholders on April 28. I’m here. 0.24 cents per share outstanding is expected during this period. Overall, Zimmer Biomet continues to deliver higher operational efficiency results and continues to see strong long-term growth prospects that will be sustainable over the next few years. We are making positive progress within.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *